Reagent plate for rapidly detecting hepatocarcinoma, making method thereof and applications

Abstract

The invention discloses an agent plate for testing hepatocarcinoma and a preparation method and the application thereof. The agent plate is composed of a rigid plate and an agent strip attached to the rigid plate, and the agent strip is formed by sequentially and closely splicing absorbent filter paper, a pyroxylin membrane, a glass fibre membrane and a sample adsorption glass fibre membrane from top to bottom, wherein a gold-labeled anti-mouse AFP monoclonal antibody is absorbed by the glass fibre membrane; an agglutinin coated detection line is arranged at one end of the pyroxylin membrane, which is adjacent to the glass fibre membrane, and a goat anti mouse IgG coated contrast line is arranged at the other end which is adjacent to the absorbent filter paper; and the lower end of the sample adsorption glass fibre membrane is provided with a row of loading holes. The agent plate for testing hepatocarcinoma has the advantages that a fluorescence microscope, an Elisa tester and other expensive instruments are not needed, and the agent plate is much more suitable for field test; the agent plate is safer since radioactive isotopes, TMB and other harmful substances or chemical substances are not needed in testing processes; test results can be preserved for a long time; and the operation of the agent plate is easy and fast, and the agent plate can be operated by a single person.

Description

technical field [0001] The invention relates to a reagent plate for detecting diseases, in particular to a reagent plate capable of rapidly and accurately detecting liver cancer, a preparation method and application thereof, and belongs to the field of biomedicine. Background technique [0002] Since alpha-fetoprotein (AFP) has a relatively specific diagnostic value for hepatocellular carcinoma, it is widely used in clinical early detection of hepatocellular carcinoma. However, long-term clinical studies have shown that AFP has certain limitations in the diagnosis of early liver cancer, as follows: 1. Poor diagnostic specificity: In addition to liver cancer, other diseases can also cause the increase of AFP in serum, especially about 20% - 40% of patients with chronic hepatitis and 20% - 50% of patients with liver cirrhosis also have elevated serum AFP, but these patients have not developed liver cancer, and the concentration of AFP in serum of chronic hepatitis or liver cir...

AI Technical Summary

Problems solved by technology

However, long-term clinical studies have shown that AFP has certain limitations in the diagnosis of early liver cancer, as follows: 1. Poor diagnostic specificity: In addition to liver cancer, other diseases can also cause the increase of AFP in serum, especially about 20% - 40% of patients with chronic hepatitis and 20% - 50% of patients with liver cirrhosis also have elevated serum AFP, but these patients have not developed liver cancer, and the concentration of AFP in serum of chronic hepatitis or liver cirrhosis can also reach a very high level after acute deterioration levels, even exceeding 1000ng / ml

Second, the missed detection rate is high: in order to improve diagnostic specificity and differentiate benign and malignant liver diseases, the existing detection standards stipulate that AFP ≥ 400 ng / ml is specified as a specific indicator of liver cancer, but only 25.7% of patients with early liver cancer have AFP ≥ 400 ng / ml ml, so only detection of AFP results in missed detection of a large number of early liver cancer patients

Images